Michael Parrott
Retina Specialist · Gainesville, FLNPI 1265641534
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,000 of the $13,479 with a category attached, or 66.8%. AbbVie accounts for 73.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $6,260 and has fallen 96.4% since, to $227 in 2025.
Across 72 payments — averaging $187.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Vertex$800
- Novartis$709
- Regeneron Healthcare Solutions, Inc.$588
- Genentech USA, Inc.$388
- Carl Zeiss Meditec, Inc.$206
- plus $852 from 12 others
Across 23 payments — averaging $6207.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$105K
- Novartis$24K
- Regeneron$14K
What the payments were for
- Consulting fees$9507%
- Speaking & faculty fees$9,00067%
- Travel & lodging$1,2169%
- Food & beverage$2,31317%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $9,936 |
| Vertex | 2 | $800 |
| Novartis | 7 | $709 |
| Regeneron Healthcare Solutions, Inc. | 15 | $588 |
| Genentech USA, Inc. | 12 | $388 |
| Carl Zeiss Meditec, Inc. | 1 | $206 |
| Cardinal Health 110 LLC | 1 | $150 |
| Medtronic | 1 | $148 |
| Apellis Pharmaceuticals, Inc. | 5 | $126 |
| Mallinckrodt Enterprises LLC | 1 | $121 |
| Spark Therapeutics, Inc. | 1 | $95 |
| Astellas Pharma US Inc | 2 | $50 |
| Genentech, Inc. | 1 | $45 |
| Halozyme Inc | 2 | $33 |
| Biogen | 1 | $28 |
| Boston Scientific | 1 | $26 |
| Alimera Sciences, Inc. | 1 | $15 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$9,709
- BEOVU$657
- Clarus 700$206
- SYNCHROMED$148
- VABYSMO$132
- ACTHAR$121
- EYLEA$116
How this compares
$13,479 in reported general payments places this provider in the 75th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SyfovrePegcetacoplan/Pf | 74 | $199,216 |
| Prednisolone Acetate | 126 | $8,284 |
| ProlensaBromfenac Sodium | 11 | $3,953 |
| MoxifloxacinMoxifloxacin Hcl | 56 | $1,495 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 52 | $697 |
| Atropine Sulfate | 17 | $610 |
| Ketorolac Tromethamine | 13 | $307 |
| Latanoprost | 40 | $298 |
| Timolol Maleate | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Apellis Pharmaceuticals, Inc.Syfovre | $126 | $199,21674 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $15 | $3,95311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 118 retina specialist providers in Florida.
Other retina specialist in Gainesville
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- John MyersPensacola$152K
- Timothy MurraySouth Miami$133K
- Adiel SmithAventura$116K
- Paul GalloglyPalm Beach Gardens$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.